Cancer Care

 

 
 
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Melanoma
Principal Investigator (?)
Study Number
W14090
Summary
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced melanoma. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.